Clinical trial
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
NCT00287248 · Institute for Neurodegenerative Disorders, Other · Completed
Key facts
| NCT number | NCT00287248 |
|---|---|
| Title | Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain |
| Official title | Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease |
| Lead sponsor | Institute for Neurodegenerative Disorders, Other |
| Collaborators | Alzheimer's Association Molecular NeuroImaging |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | [123I] IMPY & SPECT Imaging |
| Enrollment | 38 |
| Start date | Feb 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Feb 6, 2006 |
| Last update posted | Mar 7, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: